Background Mitoxantrone-based chemotherapy palliates pain without extending survival in
men with progressive androgen-independent prostate cancer. We compared docetaxel plus …

We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic
ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low …

BACKGROUND: Sipuleucel‐T is an investigational active cellular immunotherapy product
designed to stimulate an immune response against prostate cancer. The safety and efficacy …

Orthotopic liver transplantation (OLT) alone for unresectable cholangiocarcinoma is often
associated with early disease relapse and limited survival. Because of these discouraging …

BACKGROUND Recent laboratory and epidemiologic studies have suggested that green
tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored …

Background: The identification of surrogate endpoints that can replace true outcome
endpoints is crucial to the rapid evaluation of new cancer drugs. Retrospective analyses of …

We attempted to induce therapeutic immunity against prostate-derived tissues in patients
suffering from progressive hormone-refractory metastatic prostate carcinoma. Thirteen …

Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic
Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and …

BACKGROUND. Outcome results of a long‐term analysis of urachal cancer using a new
staging system are presented. METHODS. The authors analyzed clinical outcomes from 49 …

BACKGROUND Prostate cancer is the most commonly diagnosed malignancy in American
men, yet treatment of its metastatic androgen‐independent form remains inadequate. This …